Javier Ampuero - Publications

The REACT Score and the Evolving Phenotypes of Decompensated Cirrhosis.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: July 22, 2026

Identifying MASLD patient eligibility for pharmacological therapy: the need to integrate evidence into clinical practice.

Journal: Nature reviews. Gastroenterology & hepatology

Published: May 20, 2026

Prevalence and incidence of chronic kidney disease in patients with primary biliary cholangitis.

Journal: Journal of gastroenterology

Published: February 07, 2026

REACT Score, a Novel Scoring System, Improves the Prediction of Non-Elective Readmissions in Patients With Decompensated Cirrhosis.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: December 29, 2025

Deciphering the role of ammonia in MASLD: From a neurotoxin to a metabolic by-product.

Journal: Gastroenterologia y hepatologia

Published: December 18, 2025

Steatotic Liver Disease at Primary Biliary Cholangitis Diagnosis: Association With Ursodeoxycholic Acid Response and Outcomes.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: November 09, 2025

Spanish clinical practice guidelines for the diagnosis and management of cholestatic liver diseases in adult and pediatric population: Joint report from AEEH and SEGHNP.

Journal: Gastroenterologia y hepatologia

Published: October 31, 2025

Validation of BMP8A fibrosis score to identify patients with metabolic dysfunction-associated steatohepatitis with advanced liver fibrosis.

Journal: Biomarker research

Published: September 03, 2025

Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (MELATOMS-1).

Journal: CNS drugs

Published: July 17, 2025

Defining Noninvasive Criteria for Indicating Drug Therapy in Metabolic Dysfunction-associated Steatotic Liver Disease in Clinical Practice.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: April 21, 2025

Predictive value of liver enzymes in long-term prognosis of hepatic Wilson disease: results from the Wilson AEEH registry.

Journal: Orphanet journal of rare diseases

Published: March 10, 2025

Genetic map of Wilson disease in Spain - A great tool to improve diagnosis and screening.

Journal: Revista espanola de enfermedades digestivas

Published: February 11, 2025

‌

The REACT Score and the Evolving Phenotypes of Decompensated Cirrhosis.

The REACT Score and the Evolving Phenotypes of Decompensated Cirrhosis.

Identifying MASLD patient eligibility for pharmacological therapy: the need to integrate evidence into clinical practice.

Identifying MASLD patient eligibility for pharmacological therapy: the need to integrate evidence into clinical practice.

Prevalence and incidence of chronic kidney disease in patients with primary biliary cholangitis.

Prevalence and incidence of chronic kidney disease in patients with primary biliary cholangitis.

REACT Score, a Novel Scoring System, Improves the Prediction of Non-Elective Readmissions in Patients With Decompensated Cirrhosis.

REACT Score, a Novel Scoring System, Improves the Prediction of Non-Elective Readmissions in Patients With Decompensated Cirrhosis.

Deciphering the role of ammonia in MASLD: From a neurotoxin to a metabolic by-product.

Deciphering the role of ammonia in MASLD: From a neurotoxin to a metabolic by-product.

Steatotic Liver Disease at Primary Biliary Cholangitis Diagnosis: Association With Ursodeoxycholic Acid Response and Outcomes.

Steatotic Liver Disease at Primary Biliary Cholangitis Diagnosis: Association With Ursodeoxycholic Acid Response and Outcomes.

Spanish clinical practice guidelines for the diagnosis and management of cholestatic liver diseases in adult and pediatric population: Joint report from AEEH and SEGHNP.

Spanish clinical practice guidelines for the diagnosis and management of cholestatic liver diseases in adult and pediatric population: Joint report from AEEH and SEGHNP.

Validation of BMP8A fibrosis score to identify patients with metabolic dysfunction-associated steatohepatitis with advanced liver fibrosis.

Validation of BMP8A fibrosis score to identify patients with metabolic dysfunction-associated steatohepatitis with advanced liver fibrosis.

Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (MELATOMS-1).

Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (MELATOMS-1).

Defining Noninvasive Criteria for Indicating Drug Therapy in Metabolic Dysfunction-associated Steatotic Liver Disease in Clinical Practice.

Defining Noninvasive Criteria for Indicating Drug Therapy in Metabolic Dysfunction-associated Steatotic Liver Disease in Clinical Practice.

Predictive value of liver enzymes in long-term prognosis of hepatic Wilson disease: results from the Wilson AEEH registry.

Predictive value of liver enzymes in long-term prognosis of hepatic Wilson disease: results from the Wilson AEEH registry.

Genetic map of Wilson disease in Spain - A great tool to improve diagnosis and screening.

Genetic map of Wilson disease in Spain - A great tool to improve diagnosis and screening.